Back to top
more

Exelixis (EXEL)

(Real Time Quote from BATS)

$26.93 USD

26.93
739,669

-0.04 (-0.15%)

Updated Aug 12, 2024 01:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

AVEO Pharmaceuticals Q3 Loss Narrows, Focus on Fotivda

AVEO Pharmaceuticals reported narrower-than-expected adjusted loss in the third quarter. Moreover, it received approval for its first drug, Fotivda, which was approved in EU for bladder cancer.

    Arena Pharmaceuticals (ARNA) Q3 Loss Widens Y/Y, Sales Beat

    Arena Pharmaceuticals (ARNA) reports another quarter of lackluster Belviq sales. However, the company is likely to advance ralinepag in phase III study based on positive data from the previous stage.

      Spectrum (SPPI) Earnings, Sales Beat Q3 Estimates

      Spectrum (SPPI) reports narrower-than-expected loss in Q3. Shares up.

        Achillion (ACHN) Q3 Loss Narrows, Pipeline Expansion in Focus

        Achillion Pharmaceuticals' (ACHN) third-quarter loss was narrower than estimates. The company is focusing on expanding its key pipeline candidate in several indications.

          Radius Health (RDUS) Earnings Miss in Q3, Tymlos in Focus

          Radius Health (RDUS) reported a wider-than-expected loss in third-quarter as expenses grew significantly for the commercialization of Tymlos.

            Agios (AGIO) Q3 Loss Narrower than Expected, Revenues Up Y/Y

            Agios (AGIO) reports narrower-than-expected loss with revenues marginally beating estimates. The top line also improves year over year, thanks to reimbursement received from Celgene.

              Zoetis (ZTS) Beats on Q3 Earnings & Sales, Ups 2017 View

              Zoetis (ZTS) reported impressive third-quarter results beating estimates on both counts. Revenues were driven by strong demand for companion animal products worldwide.

                Geron (GERN) Q3 Loss Narrower Than Expected, Sales Miss

                Geron's (GERN) loss per share in the third quarter was narrower than expected. However, revenues missed estimates. Imetelstat remains in focus.

                  Exelixis (EXEL) Beats Q3 Earnings on Solid Cabometyx Sales

                  Exelixis (EXEL) beat both earnings and sales estimates in the third quarter fueled by strong demand for Cabometyx for RCC.

                    Conatus (CNAT) Loss Wider Than Expected in Q3, Sales Miss

                    Conatus (CNAT) reports wider-than-expected loss in Q3. However, revenues significantly increased year over year.

                      Sucampo (SCMP) Beats on Q3 Earnings & Revenues, Ups '17 View

                      Sucampo Pharmaceuticals' (SCMP) Amitizia recorded strong sales in the United States and Japan, which drove the company's top line in Q3. The company is also working on expanding its Amitizia's label.

                        Intercept (ICPT) Q3 Loss Narrower Than Expected, Sales Beat

                        Intercept's (ICPT) third-quarter results were encouraging as loss was narrower than expected while Ocaliva registered a sequential increase.

                          Acorda (ACOR) Q3 Earnings Lag Estimates, Revenues Up Y/Y

                          Acorda's (ACOR) performance in Q3 misses earnings and revenue estimates. However, the company's key drug Ampyra witnessed increase in sales year over year and inched up sequentially.

                            Shire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong

                            Shire (SHPG) reported better-than-expected third-quarter earnings and also registered strong growth in immunology franchise. Shares were up in response.

                              What's in the Offing for Exelixis (EXEL) in Q3 Earnings?

                              Exelixis, Inc. (EXEL) received a major boost with the FDA's approval of Cabometyx tablets and we expect investor focus on the drug's uptake when it reports third-quarter results.

                                Bristol-Myers (BMY) Misses on Q3 Earnings, Opdivo in Focus

                                Bristol-Myers (BMY) Q3 earnings miss estimates while revenues beat the same. Opdivo's label was expanded to two more indications.

                                  Arpita Dutt headshot

                                  Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug

                                  Key highlights include regulatory updates from Exelixis (EXEL) and Spark Therapeutics and pipeline updates from Regeneron and Ionis among others.

                                    Company News For Oct 17, 2017

                                    Companies in the news are: EXEL,TSLA,SONC,BMI

                                      FDA Grants Priority Review for Exelixis' RCC Drug Cabomteyx

                                      Exelixis (EXEL) announced that the FDA has granted priority review to its supplemental New Drug Application (sNDA) for kidney cancer drug Cabomteyx.

                                        Exelixis (EXEL) Looks Good: Stock Adds 17.2% in Session

                                        Exelixis (EXEL) was a big mover last session, as the company saw its shares rise more than 17% on the day amid huge volumes.

                                          Can Exelixis (EXEL) Run Higher on Strong Earnings Estimate Revisions?

                                          Exelixis (EXEL) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.

                                            Exelixis Submits sNDA for Kidney Cancer Drug Cabometyx

                                            Exelixis, Inc. (EXEL) submitted its supplemental New Drug Application (sNDA) to the FDA for Cabometyx tablets for patients with previously untreated kidney cancer.

                                              Juno Therapeutics (JUNO) Q2 Loss Widens, Revenues Surpass

                                              Juno Therapeutics (JUNO) reports wider-than-expected loss but revenues beat estimates. However, revenue decreased year-over-year.

                                                Agenus (AGEN) Q2 Loss Narrower Than Expected, Revenues Lag

                                                Agenus Inc. (AGEN) witnesses narrower-than-expected loss and also misses revenue estimates. However, the company is progressing well with the candidates in its pipeline in Q2.

                                                  AMAG Pharma (AMAG) Incurs Narrower-than-Expected Loss in Q2

                                                  AMAG Pharmaceuticals, Inc. (AMAG) posted narrower-than-expected loss and slightly beat revenue estimates in Q2.